C
CERo Therapeutics Holdings, Inc. (CERO)
OQB – Real Time Price. Currency in USD
0.01
+0.00 (37.50%)
At close: Jun 26, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
OQB – Real Time Price. Currency in USD
0.01
+0.00 (37.50%)
At close: Jun 26, 2026, 4:00 PM EDT
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. Kristen Pierce Ph.D. | Chief Development Officer |
| Dr. Lawrence Corey M.D. | Co-founder & Head of Scientific Advisory Board |
| Mr. Andrew Albert Kucharchuk M.B.A. | Chief Financial Officer |
| Mr. Christopher B. Ehrlich M.B.A. | CEO & Chair |
| Date | Type | Document |
|---|---|---|
| 2026-05-29 | 8-K | ea0292715-8k_cero.htm |
| 2026-05-15 | 10-Q | ea0290300-10q_cerotherap.htm |
| 2026-05-01 | 8-K | ea028870101-8k_cero.htm |
| 2026-04-30 | 10-K/A | ea0288361-10ka1_cero.htm |
| 2026-04-15 | 10-K | ea0285271-10k_cero.htm |
| 2026-04-14 | 8-K | ea0286319-8k_cero.htm |
| 2026-04-01 | NT 10-K | ea0284239-nt10k_cero.htm |
| 2026-03-11 | 8-K | ea0280905-8k_cero.htm |
| 2026-02-13 | 8-K | ea0276984-8k_ceroa.htm |
| 2026-02-04 | 8-K | ea0275412-8k_cero.htm |